Edwards Lifesciences Corp. closed 26.14% below its 52-week high of $96.12, which the company reached on March 28th.

Spire Wealth Management lessened its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.55 per share, reflecting a decline of 14.1% compared to the same period last ...

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...

In wrapping up the 2023-24 term and embarking on the 2024-25 term, the Supreme Court was asked to decide a number of intellectual property cases. The ...

Mettler-Toledo (MTD) came out with quarterly earnings of $12.41 per share, beating the Zacks Consensus Estimate of $11.69 per share. This compares to earnings of $9.40 per share a year ago. These ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

Find insight on AstraZeneca, Eli Lilly, Siemens Healthineers and more in the latest Market Talks covering Health Care.